Introduction
The progression of aggressive breast cancer is characterized by genomic instability leading to multiple genetic defects, phenotypic diversity, chemoresistance, and poor outcome (Lengauer et al., 1998; Loeb, 2001 ). An imbalance between oncogene and tumor suppressor activities plays an important role in the onset of breast cancer through the inactivation of G 1 /S and/or G 2 /M checkpoints, which normally ensure the orderly progression of cell cycle events (Hartwell and Weinert, 1989) . In normal cells, checkpoint activation in response to DNA damage is mediated by p53 through upregulation of its downstream targets, and consequent cell cycle arrest (Wang et al., 1999; Jin and Levine, 2001; Taylor and Stark, 2001) . Recently, the centrosome has been implicated in the pathogenesis of cancer through the development of multipolar mitotic spindles leading to chromosomal instability and clonal heterogeneity (Brinkley, 2001; D'Assoro et al., 2002b) . The centrosome is the major microtubule-organizing center of the cell and is duplicated once during a normal cell cycle to give rise to two centrosomes that function as the spindle poles during mitosis (Kirschner and Mitchison, 1986; Kellogg, 1989; Palazzo, 2003) . Therefore, tight coordination between the centrosome duplication and DNA replication cycles is essential to ensure equal segregation of sister chromatids during cell division (Sluder and Hinchcliffe, 2000) . However, centrosome duplication is not strictly dependent on DNA replication since the centrosome and DNA cycles can be uncoupled (Balczon et al., 1995) . In cancer, loss of coordination between the centrosome and DNA cycles may lead to centrosome amplification, increased frequency of multipolar mitoses, and chromosomal instability (Lingle et al., 1998 (Lingle et al., , 2002 Pihan et al., 2001; D'Assoro et al., 2002a) . Tumor suppressors and cdk/cyclins play an important role in coordinating centrosome duplication with cell cycle events. In mouse model studies, loss of p53 by gene targeting and gain-of-function p53 mutations resulted in the development of centrosome amplification and aberrant mitoses (Fukasawa et al., 1996; Fry et al., 1999; Murphy and Rosen, 2000; Tarapore et al., 2001) . Furthermore, cyclins E and A have been demonstrated to be key regulators of the centrosome cycle (Hinchcliffe et al., 1999; Meraldi et al., 1999; Faivre et al., 2002; Okuda, 2002) , and p53 mutations associated with cyclin E overexpression synergistically increase the frequency of centrosome defects (Mussman et al., 2000) . Centrosome duplication is also coordinated with DNA synthesis through the phosphorylation status of retinoblastoma and consequent activation of the E2F transcription factor (Angus et al., 2002) . A role for p53 and retinoblastoma (Rb) in this process is also suggested by studies where inactivation of these tumor suppressors after infection with high-risk human papillomaviruses carrying E6 and E7 viral oncogenes leads to centrosome amplification (Duensing and Munger, 2002; Riley et al., 2003) . In human breast cancer, however, the relationship between cell cycle checkpoint defects, DNA damage and development of centrosome amplification has not been extensively investigated. To elucidate the molecular mechanisms linking G 1 /S checkpoint activity to the centrosome duplication cycle, we studied the effect of drugs inducing genotoxic stress in breast tumor-derived cell lines with different p53 backgrounds. Our results demonstrate that p53 activity, through upregulation of p21 WAF1 and retinoblastoma hypophosphorylation, is essential for the maintenance of centrosome homeostasis following DNA damage. In the breast cancer models studied here, inactivation of the p53 pathway also leads to the upregulation of cyclin A, suggesting that control of centrosome duplication may depend on a balance between positive and negative regulators acting at the G 1 /S transition of the cell cycle.
Results

p53 status and centrosome phenotype in breast cancer cell lines
In order to elucidate how p53 affects centrosome phenotype in breast cancer cell lines, we compared MCF-7 cells, which carry wild-type p53, a variant of this cell line carrying a dominant-negative p53 mutation DNp53 ), and MDA-MB 231 cells with mutant p53 at both alleles (Gartel et al., 2003) . We analysed p53 expression, centrosome characteristics, and cell cycle profiles for each cell line. Western blot analysis for p53 showed that MCF-7 cells exhibited a low level of the wild-type protein, while vMCF-7
DNp53 and MDA-MB 231 cells showed a high level of mutant p53 expression ( Figure 1a) . Immunofluorescence was performed to label centrioles and pericentriolar material using primary antibodies against the centrosome proteins centrin and pericentrin, respectively. MCF-7 cells showed a normal centrosome phenotype with two or four centrioles according to the phase of the cell cycle (Figure 1b, e) . The vMCF-7
DNp53 cells exhibited normal centrosomes; however, they showed a higher percentage of cells with duplicated centrosomes (total of four centrioles) compared to the parental cell line (Figure 1c , e). To determine if the difference in centrosome number was related to cell cycle progression, we performed FACS analysis and found that the vMCF-7
DNp53 cell line showed a decrease in the proportion of cells in G 1 and a corresponding increase in the S and G 2 /M phases of the cell cycle (Figure 1f ). These results show that while partial inhibition of p53 function accelerated both entry into S phase and the centrosome duplication cycle, centrosome duplication nonetheless remained coordinated with DNA replication and cell cycle progression. To determine if the complete abrogation of p53 function may have different effects on centrosome characteristics, we further analysed centrosome phenotype in the breast cancer cell line MDA-MB 231, which carries only mutant p53. Immunofluorescence analysis (Figure 1d) showed amplified centrosomes, which were characterized by supernumerary centrioles and excess pericentriolar material in 56% of the cells. FACS analysis (Figure 1f ) of these cells, however, showed a lower percentage of cells in the S and G2/M phases of the cell DNp53 cell line. Taken together, these observations led us to investigate further the role of p53 abrogation in uncoupling the centrosome and DNA cycles and the generation of amplified centrosomes.
Effect of genotoxic stress on the centrosome duplication cycle in breast cancer cells
In normal cells, p53 functions to monitor genomic integrity, and following DNA damage this tumor suppressor mediates molecular responses leading to cell cycle arrest, DNA repair, or programmed cell death. We used hydroxyurea (HU), an inhibitor of ribonucleotide reductase activity, to induce replication stress DNA damage (Sakano et al., 2001) , activate the G 1 /S checkpoint, and to determine how the centrosome duplication cycle was affected. In these experiments, DNp53 , and MDA-MB 231 cells were treated with 2 mM HU for 48 h and analysed for DNA synthesis arrest by FACS analysis and centrosome phenotype by immunofluorescence and electron microscopy. FACS analysis showed that HU treatment blocked DNA replication in all three cell lines regardless of their p53 status (Figure 2 ). High magnification immunofluorescence images, of cells before and after HU treatment, labeled for pericentriolar material and centrioles, using pericentrin and centrin antibodies, respectively, are illustrated in Figure 3a . Quantitative analysis of centrosome number and size for each cell type showed a different centrosome phenotype following HU treatment ( Figure 3b and c and Table 1 ). In MCF-7 cells, the centrosome duplication cycle was arrested following HU treatment since most of the cells showed normal centrosomes with two or four centrioles and did not show an increase in centrosome size ( Figure 3a upper row, b and c and Table 1 ). Therefore, the DNA and centrosome cycles in MCF-7 cells remained tightly coordinated, even following experimentally introduced DNA replication blockade. In contrast, vMCF-7 DNp53 cells generated amplified centrosomes with 45% of the cells showing greater than four centrioles after treatment with HU ( Figure 3a middle row, b). Interestingly, in these cells, centriole overduplication was not accompanied by a dramatic increase of the centrosome size ( Figure 3c and Table 1 ). However, a striking change in centrosome structure was observed in MDA-MB 231 cells following HU treatment (Figure 3a lower row). These cells, which showed amplified centrosomes at the outset, developed hyperamplified centrosomes characterized by dramatic centriole overduplication and a further increase in centrosome size (Figure 3a lower row, b and c and Table 1 ). Ultrastructural analyses of centrosomes confirmed the immunofluorescence findings. Figure 4 shows representative images of MCF-7 centrosomes, where more than four centriole profiles were never seen in the same section. In MDA-MB 231, however, cell sections with more than four centriole profiles were DNp53 and MDA-MB 231 cells showed an increase in centrosome size following HU or DR treatment frequently observed, particularly following HU treatment. To determine if other genotoxic agents result in the development of centrosome amplification, we investigated the effect of the daunorubicin (DR) on centrosome duplication in the three breast cancer cell lines. The anthracycline DR induces damage to DNA through intercalation-induced distortion of the double helix, or stabilization of the cleavable complex formed between DNA and topoisomerase II (Rubin and William, 2003) . Following treatment with DR, MCF-7 cells maintained a normal centrosome phenotype similar to that seen following HU treatment (Figure 3b , c and Table 1 ). While vMCF-7
Dnp53 and MDA-MB 231 cells developed centrosome amplification and hyperamplification, respectively, following DR treatment (Figure 3b , c and Table 1 ). These findings suggest that, in cells with intact p53 function, genotoxic stress may trigger cell cycle checkpoints that normally ensure coordination of the centrosome duplication and DNA cycles.
Loss of p53 activity uncouples the centrosome cycle from DNA synthesis through deregulation of the G 1 /S cell cycle checkpoint To determine the mechanism by which p53 integrates the centrosome duplication and DNA replication cycles, we investigated the expression and localization of p53 and its downstream target p21 WAF1 , following DNA damage. Immunofluorescence labeling of MCF-7 cells showed a quantitative increase in both p53 and p21 WAF1 nuclear localization in HU-treated cells (Figure 5a upper  row, b) . In contrast, vMCF-7
DNp53 cells, regardless of a higher nuclear localization of p53 following HU treatment, showed a reduced p21 WAF1 nuclear accumulation compared to the parental cell line (Figure 5a middle  row, b) . MDA-MB 231 cells showed the mutated form of p53 highly expressed and localized in the nucleus before and following DNA damage. However, in these cells, HU treatment did not result in p21 WAF1 induction, indicating the complete abrogation of the p53 pathway (Figure 5a lower row, b) . We then performed a time course Western blot analysis in order to establish the relationship between integrity of the p53 pathway and activation of the G 1 /S cell cycle checkpoint in the three cell lines. Activation of the G 1 /S checkpoint was present only in the MCF-7 cell line where HU treatment resulted in a rapid increase of p53 protein that was followed by induction of p21 WAF1 and subsequent hypophosphorylation of retinoblastoma ( Figure 6 ). In contrast, both vMCF-7
DNp53 and MDA-MB 231 cells showed a high level of mutant p53 expression, low p21 WAF1 expression, and a high level of retinoblastoma phosphorylation ( Figure 6 ). These results indicate a defect in G 1 /S checkpoint activation after DNA damage in the cell lines with abrogated p53 function. Interestingly, while DNp53 (middle row), and MDA-MB 231 (lower row) cells before (Control) and after HU treatment (48 h). Nuclei were stained in blue with DAPI, while p53 and p21 WAF1 were labeled green and red, respectively. Each row illustrates the individual fluorescence channels and an overlay image of p53 and p21 WAF1 . Following HU treatment, MCF-7 cells showed an increase of p53 and p21 WAF1 nuclear accumulation, while vMCF-7
DNp53 cells also showed a higher level of nuclear p53, but did not show a corresponding increase of nuclear p21 WAF1 . MDA-MB 231 cells showed nuclear localization of p53 in most cells, but there was no induction of p21 WAF1 , following HU treatment. 
Cdk activity is required for centrosome hyperamplification following HU treatment in the MDA-MB 231 cell line
In order to further investigate the role of cyclin/cdk activity in the development of centrosome amplification following DNA damage, we determined the effect of roscovitine, a potent inhibitor of the cdk activity (Mgbonyebi et al., 1999) , on the level of expression of key G 1 /S cell cycle checkpoint regulators and on HUinduced centrosome hyperamplification in the MDA-MB 231 cell line. Roscovitine treatment resulted in a decrease in both Rb phosphorylation and cyclin A expression in HU-treated cells, indicating an effective arrest in the progression of the G1/S cell cycle machinery (Figure 7a ). Immunofluorescence analysis also demonstrated that roscovitine treatment effectively reduced centrosome hyperamplification induced by HU (Figure 7b-f, Table 1 ). These experiments demonstrated that in cancer cells lacking p21 expression, it is possible to experimentally block centrosome hyperamplification through the inhibition of cyclin/cdk activity. These results further substantiate an interplay between the p53-mediated G1/S cell cycle checkpoint, retinoblastoma function, and cyclin A expression in the maintenance of centrosome homeostasis following genotoxic stress in breast cancer cells.
Discussion
Deregulation of cell cycle checkpoints, development of genomic instability, and aneuploidy are hallmarks of breast cancer (Anbazhagan et al., 1991; Wenger et al., 1993; Gunther et al., 1997) . Genomic instability represents a major problem in the management of breast cancer patients due to the generation of diverse tumor cell phenotypes, which in turn may facilitate the development of chemoresistance and tumor progression (Khong and Restifo, 2002; Pinto et al., 2003) . However, molecular mechanisms associated with the development of genomic instability and aneuploidy are poorly understood in breast cancer. Several studies suggest that deregulation of the centrosome cycle may lead to the development of chromosomal instability through the formation of multipolar mitotic spindles and unequal chromosome segregation (Lingle and Salisbury, 1999; Goepfert et al., 2002; Kramer et al., 2002; Lingle et al., 2002; Duensing and Munger, 2003; Pihan et al., 2003) . The tumor suppressor gene p53, mutated in more than 50% of human cancers (Lane and Benchimol, 1990; Levine et al., 1991) , plays an important role in the maintenance of centrosome homeostasis since loss of p53 function can lead to centrosome defects (Fukasawa et al., 1996; Borel et al., 2002; Tarapore and Fukasawa, 2002) . However, since p53-null mice develop normally and have normal centrosomes in most of their cells, the development of centrosome amplification in this model may result only after failure of p53 function following genotoxic stress. Furthermore, the cdk/cyclins have also been implicated in the control of centrosome duplication (Hinchcliffe et al., 1999; Lacey et al., 1999; Meraldi et al., 1999) and changes in their expression correlate with centrosome amplification (Kronenwett et al., 2003) , suggesting an interplay between p53 and cdk/cyclin (p53, p21 WAF1 , phospho-Rb, cyclin E, and cyclin A) was analysed before and in a time course series following HU treatment. Whole-cell lysate (20 mg) was loaded in each lane. bActin was used as loading control regulatory pathways in coordinating centrosome duplication with other cell cycle events.
In order to investigate the role of the G 1 /S cell cycle checkpoint in the development of centrosome amplification in cancer, centrosome characteristics were monitored in human breast cancer cell lines with intact or abrogated G 1 /S checkpoint function. We compared the behavior of the breast tumor-derived cell lines DNp53 , and MDA-MB 231 and determined that the progressive loss of p53 function leads to the acquisition of increasingly severe centrosome defects following genotoxic stress. MCF-7 cells, which have wild-type p53, arrested the centrosome duplication cycle when DNA damage was introduced by treatment with either HU or DR. In this cell line, activation of the G 1 /S cell cycle checkpoint was indicated by an increase of p53 and p21 WAF1 expression and their nuclear localization, retinoblastoma hypophosphorylation, and reduction of cyclin A levels. Therefore, in these cells, activation of the G1/S checkpoint in response to genotoxic stress led to inhibition of centrosome overduplication and maintenance of a normal centrosome phenotype. In contrast, DNA damage led to centrosome amplification in vMCF-7 DNp53 cells. In these cells, the introduced dominant-negative p53 led to weak induction of p21 WAF1 expression, high level of phosphorylated retinoblastoma, and deregulation of cyclin A expression, indicating a failure of G 1 /S cell cycle checkpoint activation. Interestingly, in vMCF-7
DNp53 cells, centrosome amplification was seen only after induction of DNA damage, since in untreated cells the majority of centrosomes showed a normal phenotype. MDA-MB 231 cells, which have mutant p53 and displayed amplified centrosomes at the outset, developed a higher grade of centrosome defect following DNA damage. In these cells, the development of centrosome hyperamplification was also associated with failure of the G1/S cell cycle checkpoint through lack of p21 WAF1 expression, retinoblastoma hyperphosphorylation, and cyclin A overexpression. Importantly, centrosome hyperamplification in these cells could be blocked by roscovitine, a potent inhibitor of cyclin/cdk activity that is currently under clinical trial (Senderowicz, 2003) . Roscovitine treatment mimicked a role for p21 in the p53-defective cell line MDA-MB 231 by effectively rescuing G1/S cell cycle checkpoint function, which was characterized by Rb hypophosphorylation and low levels of cyclin A expression.
In conclusion, the findings reported here suggest that p53 and cyclin/cdk pathways regulate centrosome homeostasis by ensuring the integrity of the G1/S cell cycle checkpoint. Furthermore, they also demonstrate that loss of p53 function alone is not sufficient to cause the development of centrosome amplification, but rather failure of the G 1 /S checkpoint activation following genotoxic stress is required to induce centriole overduplication. This mechanism may play an important role in the development of centrosome amplification during breast cancer development. However, these findings also have important clinical implications for the treatment of breast cancer because they suggest that tumor cells with defective G 1 /S cell cycle checkpoint function may develop or increase centrosome amplification following treatment with genotoxic anticancer drugs. This process may facilitate the development of higher clonal heterogeneity leading to chemoresistance and poor outcome. To overcome the complications associated with centrosome amplification for this subset of breast cancer patients, treatment with cdk inhibitors in combination with anticancer genotoxic drugs may provide an attractive therapeutic approach.
Materials and methods
Cell lines
The human breast cancer cell lines (MCF-7 and MDA-MB 231) were obtained from ATCC (Manassas, VA, USA) and maintained in EMEM medium containing 5 mM glutamine, 1% penicillin/streptomycin, and 10% FBS at 371C in 5% CO 2 atmosphere. MCF-7 cells were supplemented with 20 mg insulin/ml, and MCF-7 cells carrying a dominant-negative p53 mutant ) were grown in selection medium containing 500 mg/ml G148.
Generation of dominant-negative p53 clones
The pCMV-p53mt135 expression vector (Clontech, Palo Alto, CA, USA) was used to generate MCF-7 clones carrying a dominant-negative p53 mutant that had a G to A conversion at nucleotide 1017. This mutant, which is characterized by a Val 135 substitution, forms a mixed tetramer with the p53 wild-type protein that is unable to activate its downstream targets, without exerting gain of function activity (Harvey et al., 1995) . MCF-7 cells were plated at a density of 3 Â 10 5 . After 24 h, cells were transfected using Fugene 6 reagent (Roche, Indianapolis, IN, USA) following the manufacture's instructions. After 48 h, cells were washed in PBS, and were selected over 3 weeks in medium containing 500 mg/ml G418. Colonies derived from single cells were isolated using cloning cylinders, followed by limiting dilution. Individual subclones were grown to 80% confluence and frozen. The subcellular localization and expression of the dominant-negative p53 in MCF-7 clones were confirmed by immunofluorescence and Western blotting analysis. Clone 8 was used for the experiments described in this study.
Induction of genotoxic stress
To investigate the relationship between centrosome duplication and G 1 /S checkpoint activation, cell lines were plated at a density of 3 Â 10 5 . After 48 h, cells were treated with 2 mM HU or 1 mM DR to induce DNA damage and analysed at different time points up to 48 h. Roscovitine (10 mg/ml) was also used to inhibit cdks activity in combination with HU in the MDA-MB 231 cell line for 48 h.
Cell cycle profile
For fluorescence-activated cell sorting (FACS) analysis, cell lines were washed with cold PBS, fixed in 95% ethanol, stained with propidium iodide for 30 min and analysed by flow cytometry using Facscan by Becton Dickinson (Franklin Lakes, NJ, USA). The resulting cell cycle profiles, based on 20 000 events, were analysed using the ModFit program by Verity Software House (Topsham, ME, USA).
Immunofluorescence
For indirect immunofluorescence analysis, cells were grown on coverslips, fixed in methanol at À201C for 10 min, blocked in 5% normal goat serum, 1% glycerol, 0.1% BSA, 0.1% fish skin gelatin, 0.04% sodium azide and incubated with primary antibodies directed against the following proteins: p53 (Santa Cruz, Santa Cruz, CA, USA) and p21 WAF1 (Oncogene, Darmstadt, Germany). For the staining of centrioles and pericentriolar material, we used antibodies against the proteins centrin and pericentrin, respectively. Coverslips were washed three times in PBS followed by incubation with secondary antibodies conjugated with Alexa 488 or Alexa 568 (Molecular Probes, Eugene, OR, USA), washed three times in PBS and finally incubated in DAPI to stain DNA. Immunofluorescence images were digitally recorded using a Nikon FXA fluorescence microscope equipped with computer-controlled focus, CCD digital camera, and Metamorph TM (Universal Imaging Corp, Downingtown, PA, USA) software. Fields were recorded at multiple focal planes and analysed and printed as maximum projections to assure that all centrioles and centrosomal structures were imaged.
Quantitative analysis of centrosome size and number
The NIH image J program was used for the quantitative analysis of centrosome size. For each cell line and treatment, centrosome area (mm 
Western blotting
For Western blot analysis, 20 mg protein of whole-cell lysate were run in 12% SDS-PAGE, transferred to PVDF membrane, fixed in 0.25% glutaraldehyde, blocked in 5% nonfat dry milk and incubated with primary antibodies against the following proteins: p53 (D07 DAKO A/S), p21 WAF1 , phosphoretinoblastoma (Sigma, St Louis, MO, USA), cyclin E and cyclin A (Santa Cruz), and b-actin (Sigma) as loading control. After washing in Tween-20 buffer, PVDF membranes were incubated with HRP secondary antibodies (Amersham, Piscataway, NJ, USA), and signal was detected using the ECL-plus reagent (Amersham) following the manufacture's instruction.
Electron microscopy
Cells were fixed in 2% glutaraldehyde in sodium phosphate buffer, pH 7.2, for 2 h, postfixed in osmium tetroxide, dehydrated through an ethanol series, and embedded in Spurr's resin. Silver-gold sections were stained in 2% aqueous uranyl acetate and Reynold's lead citrate, observed using a JEOL 1200 EX electron microscope and recorded digitally.
